Drug intelligence / Profile preview

candesartan cilexetil + amlodipine

Development stage
Phase 4
Lead developer
Aspen Pharmacare
Modality
Small Molecules
Administration
Oral
01

Overview

Clodipan is a fixed-dose combination of candesartan cilexetil, an angiotensin II receptor blocker (ARB), and amlodipine, a dihydropyridine calcium channel blocker (CCB). It is approved for the treatment of hypertension (high blood pressure). Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation and decreased aldosterone secretion. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and reduced peripheral vascular resistance. Together, these complementary mechanisms provide synergistic blood pressure reduction and organoprotective effects.

Brand names
Clodipan
Other names
candesartan cilexetil + amlodipine besilatecandesartan cilexetil and amlodipinecandesartan cilexetil/amlodipinecandesartan/amlodipine
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)AGTR2 (AT2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)CACNA1S (Voltage-dependent L-type calcium channel subunit alpha-1S)

Beyond the preview

Go deeper on candesartan cilexetil + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan cilexetil + amlodipine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call